Beryl Drugs FY26 Performance Hit by Production Halt

Beryl Drugs' revenue for the year ended March 31, 2026, was ₹19.31 crore, a 14.38% decrease from ₹22.55 crore in the previous year.
Net profit for FY26 declined by 26.32% to ₹0.42 crore, down from ₹0.57 crore in FY25.

Reader Takeaway: Revenue and profit decline due to production halt, but regulatory issue resolved.

What just happened

Beryl Drugs Limited reported its financial results for the fiscal year ended March 31, 2026. Total revenue from operations stood at ₹19.31 crore, a notable decrease from ₹22.55 crore in the previous fiscal year. Net profit also saw a significant drop, settling at ₹0.42 crore compared to ₹0.57 crore in FY25.

Why this matters

The decline in financial performance is directly linked to a mandated halt in manufacturing activities at the company's Blow Fill Seal (BFS) section. This regulatory intervention, which lasted from January 20, 2025, to November 2025, significantly impacted operational scale and, consequently, revenue and profitability.

The backstory

The Madhya Pradesh Food and Drugs Administration ordered Beryl Drugs to stop production in its BFS section due to compliance issues. The company has since undertaken rectification measures and complied with the necessary protocols, leading to the revocation of the order in November 2025.

What changes now

With the BFS production suspension lifted, Beryl Drugs can now focus on normalizing its operations and recovering lost ground. The company also needs to address an unrecorded professional tax liability, for which it has not yet obtained registration. Additionally, the adoption of Ind AS 116 has led to accounting adjustments on the balance sheet.

Risks to watch

Investors should closely monitor the company's progress in addressing the unrecorded professional tax liability. Failure to register and account for this liability could pose future financial risks. The impact of the Ind AS 116 adoption on the company's financial statements also remains a point to track.

Peer comparison

While specific peer financial data for FY26 is not provided in the filing, the pharmaceutical sector generally experiences fluctuations based on regulatory approvals, manufacturing efficiencies, and market demand.

Context metrics (time-bound)

• Revenue FY26: ₹19.31 crore (down 14.38% from FY25)
• Net Profit FY26: ₹0.42 crore (down 26.32% from FY25)
• BFS Production Halt: January 20, 2025 - November 2025

What to track next

Investors should look for signs of operational recovery and revenue growth in the upcoming quarters. Monitoring management's strategy to address the professional tax liability and any further impact from lease accounting standards will be crucial.